EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz iD, Zbigniew Siudak iD, Jakub Batko iD, Stanisław Bartuś iD, Agata Krawczyk-Ożóg iD

Medicina · 12.07.2024 · 60 (7) · 1124

DOI: 10.3390/medicina60071124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 12.07.2024. Verfasst von Renata Rajtar-Salwa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department of Cardiology and Cardiovascular Interventions, University Hospital, Macieja Jakubowskiego 2 Street, 30-688 Krakow, Poland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hypercholesterolemia, Anticholesteremic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectiveness and safety profile of alirocumab, evolocumab, and inclisiran in lipid reduction. Materials and Methods: A cohort of 51 patients (median (Q1–Q3) age: 49.0 (39.5–57.5) years) was analyzed. Eligibility included an LDL-C level > 2.5 mmol/L while on the maximum tolerated dose of statin and ezetimibe, a diagnosis of familial hypercholesterolemia, or a very high risk of cardiovascular diseases following myocardial infarction within 12 months prior to the study. Follow-ups and lab assessments were conducted at baseline (51 patients), 3 months (51 patients), and 15 months (26 patients) after the treatment initiation.

Results

Median initial LDL-C levels 4.1 (2.9–5.0) mmol/L, decreasing significantly to 1.1 (0.9–1.6) mmol/L at 3 months and 1.0 (0.7–1.8) mmol/L at 15 months (p < 0.001). Total cholesterol also reduced significantly compared to baseline at both intervals (p < 0.001). No substantial differences in LDL-C or total cholesterol levels were observed between 3- and 15-month observations (p > 0.05). No statistically significant differences were noted in cholesterol reduction among the alirocumab, evolocumab, and inclisiran groups at 3 months. The safety profile was favorable, with no reported adverse cardiovascular events or significant changes in alanine transaminase, creatinine, or creatine kinase levels.

Conclusions

Alirocumab, evolocumab, and inclisiran notably decreased LDL-C and total cholesterol levels without significant adverse effects, underscoring their potential as effective treatments in patients who do not achieve lipid targets with conventional therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHypercholesterolemiaAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLHumansMaleFemaleMiddle AgedAdultAntibodies, MonoclonalTreatment OutcomeCohort StudiesRNA, Small Interfering

Stichwörter der Autor:innen

alirocumabevolocumabhypercholesterolemiainclisiranproprotein convertase subtilisin/kexin type 9 inhibitors

Substanzen

Antibodies, Monoclonal, HumanizedevolocumabalirocumabAnticholesteremic AgentsCholesterol, LDLAntibodies, MonoclonalALN-PCSRNA, Small Interfering

Autor:innen und Institutionen

  • Clinical Department of Cardiology and Cardiovascular Interventions, University Hospital, Macieja Jakubowskiego 2 Street, 30-688 Krakow, Poland.
  • 2nd Department of Cardiology, Jagiellonian University Medical College, Macieja Jakubowskiego 2 Street, 30-688 Krakow, Poland.
  • Collegium Medicum, Jan Kochanowski University in Kielce, 25-369 Kielce, Poland.
  • Department of Anatomy, Jagiellonian University Medical College, 12 Kopernika Street, 31-034 Krakow, Poland.

ORCID-Profile: Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg

Zitieren

APA

Rajtar-Salwa, R., Bobrowska, B., Socha, S., Dziewierz, A., Siudak, Z., Batko, J., Bartuś, S., & Krawczyk-Ożóg, A. (2024). Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina, 60(7), 1124. https://doi.org/10.3390/medicina60071124

Vancouver

Rajtar-Salwa R, Bobrowska B, Socha S, Dziewierz A, Siudak Z, Batko J, et al. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina. 2024;60(7):1124. doi:10.3390/medicina60071124

BibTeX
@article{RajtarSalwa2024,
  author = {Rajtar-Salwa, Renata and Bobrowska, Beata and Socha, Sylwia and Dziewierz, Artur and Siudak, Zbigniew and Batko, Jakub and Bartuś, Stanisław and Krawczyk-Ożóg, Agata},
  title = {Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk},
  journal = {Medicina},
  year = {2024},
  volume = {60},
  number = {7},
  pages = {1124},
  doi = {10.3390/medicina60071124}
}
Kostenlos starten →